Cytotoxicity of Campath-1h for acute lymphoblastic leukemia cells carrying the t(12;21) translocation

Haematologica

Volumn 91, Issue 3, 2006, Pages 291-

  Van Der Velden, Vincent H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 21; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; NONHODGKIN LYMPHOMA; NOTE; PROLYMPHOCYTIC LEUKEMIA; T CELL LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 33645402978     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Moreton P, Hillmen P. Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol 2003;30:493-501.
2. Dearden C. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm 2004;19:391-8.
3. Golay J, Cortiana C, Manganini M, Cazzaniga G, Salvi A, Spinelli O, et al. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to Campath-1h-mediated cell lysis. Haematologica 2006;91:322-30.
4. van der Velden VHJ, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients. Leukemia 2004;18:983-8.